| Dr Jeffrey Thomas Janning, MD | |
|
830 Thomas More Pkwy, Suite 200 A, Edgewood, KY 41017-5102 | |
| (859) 341-3383 | |
| (859) 578-2013 |
| Full Name | Dr Jeffrey Thomas Janning |
|---|---|
| Gender | Male |
| Speciality | Pediatric Medicine |
| Experience | 40 Years |
| Location | 830 Thomas More Pkwy, Edgewood, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760447619 | NPI | - | NPPES |
| 64255862 | Medicaid | KY | |
| 2389464 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 25586 (Kentucky) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group, Inc | 2163326240 | 693 |
News Archive
Queen's University Belfast is leading a major new international initiative into modern cancer care medicine which was announced today in Washington D.C.
Intensified and urgent action is needed in the Greater Darfur Region of western Sudan to address one of the most severe humanitarian emergencies today. Given the current situation, the humanitarian crisis will last several months.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).
Silence Therapeutics plc announces that the Company and AstraZeneca have agreed to a one-year extension of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in March 2008, the companies are leveraging a number of Silence's proprietary lipid delivery and targeting technologies to develop new and enhanced delivery approaches for RNA interference (RNAi) therapeutics.
› Verified 2 days ago
| Entity Name | Summit Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881026169 PECOS PAC ID: 2163326240 Enrollment ID: O20031120000738 |
News Archive
Queen's University Belfast is leading a major new international initiative into modern cancer care medicine which was announced today in Washington D.C.
Intensified and urgent action is needed in the Greater Darfur Region of western Sudan to address one of the most severe humanitarian emergencies today. Given the current situation, the humanitarian crisis will last several months.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).
Silence Therapeutics plc announces that the Company and AstraZeneca have agreed to a one-year extension of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in March 2008, the companies are leveraging a number of Silence's proprietary lipid delivery and targeting technologies to develop new and enhanced delivery approaches for RNA interference (RNAi) therapeutics.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey Thomas Janning, MD Po Box 635283, Cincinnati, OH 45263-5283 Ph: (859) 341-3383 | Dr Jeffrey Thomas Janning, MD 830 Thomas More Pkwy, Suite 200 A, Edgewood, KY 41017-5102 Ph: (859) 341-3383 |
News Archive
Queen's University Belfast is leading a major new international initiative into modern cancer care medicine which was announced today in Washington D.C.
Intensified and urgent action is needed in the Greater Darfur Region of western Sudan to address one of the most severe humanitarian emergencies today. Given the current situation, the humanitarian crisis will last several months.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).
Silence Therapeutics plc announces that the Company and AstraZeneca have agreed to a one-year extension of their ongoing small interfering RNA (siRNA) delivery collaboration. Under this collaboration, which was originally entered into in March 2008, the companies are leveraging a number of Silence's proprietary lipid delivery and targeting technologies to develop new and enhanced delivery approaches for RNA interference (RNAi) therapeutics.
› Verified 2 days ago
Dr. Lisa Williams Miller, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 108 Beech Dr., Edgewood, KY 41017 Phone: 859-331-8655 Fax: 859-341-7198 | |
Dr. Griffith Ernest Quinby Jr., MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 233 Colony Dr., Edgewood, KY 41017 Phone: 859-655-5642 | |
Dr. Radhika Bala Ramesh, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 20 Medical Village Dr, Ste 102, Edgewood, KY 41017 Phone: 859-341-1011 Fax: 859-341-7198 | |
Dr. Meredith A Landorf, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 830 Thomas More Pkwy, Edgewood, KY 41017 Phone: 859-301-8686 | |
Dr. Kevin Joseph Kelly, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 20 Medical Village Dr, Suite 102, Edgewood, KY 41017 Phone: 859-341-1011 Fax: 859-341-7198 | |
Jeffrey A Whitsett, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Village Dr, Edgewood, KY 41017 Phone: 859-301-2423 Fax: 859-301-2066 | |
Mrs. Jamie D Mudd, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 20 Medical Village Dr., Suite 102, Edgewood, KY 41017 Phone: 859-341-1011 Fax: 859-341-7198 |